

Form PTO-1449 (modified)

Atty. Docket No.
UVMO:021USSerial No.
10/665,377

List of Patents and Publications for Applicant's



Applicant
William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT


(Use several sheets if necessary)

Filing Date:
September 18, 2003Group:
1624U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,436,249	07/25/95	Dappen <i>et al.</i>	514	279	05/16/94
	A2	5,922,887	07/13/99	Dondio and Ronzoni	548	539	05/20/96
	A3	6,359,111	05/19/02	Meyer and Kasina	530	302	05/27/99
	A4	5,298,622	03/29/94	Portoghese <i>et al.</i>	546	15	05/12/93
	A5	5,457,208	10/10/95	Portoghese and Olmsted	546	35	06/21/93
	A6	4,816,586	03/28/89	Portoghese	544	340	07/29/87

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 99/67206	12/29/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Abdelhamid <i>et al.</i> , "Selective blockage of Delta opioid receptors prevents the development of morphine tolerance and dependence in mice," <i>J. Pharmacol. Exp. Ther.</i> , 258(1):299-303, 1991.
	C2	Akil <i>et al.</i> , "Endogenous opioids: biology and function," <i>Annual Rev. Neurosci.</i> , 7:223-255, 1984.
	C3	Ananthan <i>et al.</i> , "Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety," <i>J. Med. Chem.</i> , 41(15):2872-2881, 1998.
	C4	Ananthan <i>et al.</i> , "Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans," <i>J. Med. Chem.</i> , 42(18):3527-3538, 1999.
	C5	Bertolucci <i>et al.</i> , "Microdialysis of opioid peptide release from the nucleus accumbens and ventral pallidum of the freely moving rat," <i>Neurosci. Abstr.</i> , 18L1368, 1992.
	C6	Blisky <i>et al.</i> , "SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist," <i>J. Pharmacol. Exp. Ther.</i> , 273(1):359-366, 1995.

25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)


Atty. Docket No.
UVMO:021USSerial No.
10/665,377

List of Patents and Publications for Applicant's

Applicant
William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
September 18, 2003Group:
1624U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Bradbury <i>et al.</i> , "Biosynthetic origin and receptor conformation of methionine enkephalin," <i>Nature</i> , 260:165-166, 1976.
	C8	Conn <i>et al.</i> , "An unusual fischer indole synthesis with 4-keto acids: an indole incorporating the terminal hydrazine nitrogen," <i>J. Org. Chem.</i> , 55(90):2908-2913, 1990.
	C9	Coombs <i>et al.</i> , "Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine," <i>Anesthesiology</i> , 62(3):358-363, 1985.
	C10	Cramer III <i>et al.</i> , "Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins," <i>J. of the Am. Chem. Soc.</i> , 110(18):5959-5967, 1988.
	C11	Dressman and Lennérnas, In: <i>Oral Drug Absorption: Prediction and Assessment (Drugs and the Pharmaceutical Sciences)</i> , Vol. 106, 2000.
	C12	Foley, In: <i>Handbook of Experimental Pharmacology</i> , Herz (ed.), Vol. 104/II: Opioids II, Springer-Verlag, Berlin, 693-743, 1993.
	C13	Gomes-Flores and Weber, "Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray," <i>Immunopharm.</i> , 48:145-156, 2000.
	C14	Hardman and Limbird, In: <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , 10 th ed., McGraw-Hill Professional Publishing, 2001.
	C15	House <i>et al.</i> , "Suppression of immune function by non-peptidic delta opioid receptor antagonists," <i>Neurosci. Lett.</i> , 198:119, 1995.
	C16	Hughes <i>et al.</i> , "Identification of two related pentapeptides from the brain with potent opiate agonist activity," <i>Nature</i> , 258:577-579, 1975.
	C17	Kaliszan <i>et al.</i> , "Gradient HPLC in the determination of drug lipophilicity and acidity," <i>Pure Appl. Chem.</i> , 73:1465-1475, 2001.
	C18	Knapp <i>et al.</i> , "Properties of TAN-67, a nonpeptidic δ -opioid receptor agonist, at cloned human δ - and μ -opioid receptors," <i>Eur. J. Pharmacol.</i> , 291(2):129-134, 1995.
	C19	Knapp <i>et al.</i> , "Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors," <i>J. Pharmacol. Exp. Ther.</i> , 277(3):1284-1291, 1996.
	C20	Koob <i>et al.</i> , "Neural substrates of opiate withdrawal," <i>TINS</i> , 15(5):186-191, 1992.

25349931.1

EXAMINER:

DATE CONSIDERED:

9/30/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
UVMO:021USSerial No.
10/665,377

List of Patents and Publications for Applicant's

Applicant
William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
September 18, 2003Group:
1624U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Liao <i>et al.</i> , "De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the δ -opioid receptor," <i>J. Med. Chem.</i> , 41(24):4767-4776, 1998.
	C22	Loh <i>et al.</i> , "Molecular characterization of opioid receptors," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 30:123-147, 1990.
	C23	Lutz and Pfister, "Opioid receptors and their pharmacological profiles," <i>J. Receptor Res.</i> , 12(3):267-286, 1992.
	C24	Martin, "Pharmacology of opioids," <i>Pharmacol. Rev.</i> , 35(4):283-323, 1983.
	C25	Okawa <i>et al.</i> , "7-arylidenenaltrexones as selective $\delta 1$ opioid receptor antagonists," <i>J. Med. Chem.</i> , 41:4177-4180, 1998.
	C26	Olson <i>et al.</i> , "Endogenous opiates: 1988," <i>Peptides</i> , 10:1253-1280, 1989.
	C27	Pert and Snyder, "Opiate receptor: demonstration in nervous tissue," <i>Science</i> , 179(4077):1011-1014, 1973.
	C28	Pfeiffer <i>et al.</i> , "Psychotomimesis mediated by $\$/kappa$ $\$$ opiate receptors," <i>Science</i> , 233(4765):774-776, 1986.
	C29	Plobeck <i>et al.</i> , "New diarylmethylpiperazines as potent and selective nonpeptidic δ opioid receptor agonists with increased in vitro metabolic stability," <i>J. Med. Chem.</i> , 43(21):3887-3894, 2000.
	C30	Olmsted <i>et al.</i> , "A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic κ address element to the δ antagonist, naltrexone: 5'[(N2-alkylamindino)methyl]naltrexone derivatives as a novel class of κ opioid receptor antagonists," <i>J. Med. Chem.</i> , 36:179-180, 1993.
	C31	Portoghese <i>et al.</i> , "7-arylidenenaltrexones as selective $\delta 1$ opioid receptor antagonists," <i>J. Med. Chem.</i> , 41:4177-4180, 1998.
	C32	Raynor <i>et al.</i> , "Pharmacological characterization of the cloned κ -, δ -, and μ - opioid receptors," <i>Molecular Pharmacol.</i> , 45:330-334, 1994.
	C33	Reid <i>et al.</i> , "Naltrexone, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation," <i>Life Sci.</i> , 52:PL67-71, 1993.
	C34	Saltzman, In: <i>Drug Delivery: Engineering Principles for Drug Therapy (Topics in Chemical Engineering)</i> , Oxford University Press, 2001.

25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)


Atty. Docket No.
UVMO:021USSerial No.
10/665,377

List of Patents and Publications for Applicant's

Applicant
William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
September 18, 2003Group:
1624U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Schiller <i>et al.</i> , "The opioid μ agonist/ δ antagonist DIPP-NH ₂ [Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats," <i>J. Med. Chem.</i> , 42(18):3520, 1999.
	C36	Sharp and Yaksh, "Pain killers of the immune system," <i>Nat. Med.</i> , 3(8):831-832, 1997.
	C37	Simon, "Opioid receptors and endogenous opioid peptides," <i>Medicinal Res. Rev.</i> , 11(4):357-374, 1991.
	C38	Stevens <i>et al.</i> , "Potent and selective indolomorphinan antagonists of the kappa-opioid receptor," <i>J. Med. Chem.</i> , 43(14):2759-2769, 2000.
	C39	Takemori and Portoghese, "Selective natrexone-derived opioid receptor antagonists," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 32:239-269, 1992.
	C40	Wei <i>et al.</i> , "N,N-diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel exceptionally selective, potent δ opioid receptor agonist with oral bioavailability and its analogues," <i>J. Med. Chem.</i> , 43(21):3895-905, 2000.


25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UVMO:021US

Serial No.

10/665,377

Applicant

William J. Welsh *et al.*

Filing Date:

September 18, 2003

Group:

1624

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>MS</i>	A7	5,578,725	11/26/96	Portoghese and Garouz-Grant	546	35	1/30/95
<i>MS</i>	A8	5,852,030	12/22/98	Nagase <i>et al.</i>	514	279	9/10/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25430107.1

EXAMINER:

DATE CONSIDERED:

9/30/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

APR 14 2005

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UVMO:021US

Serial No.

10/665,377

Applicant

William J. Welsh *et al.*

Filing Date:

September 18, 2003

Group:

1624

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents


Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C41	Peng <i>et al.</i> , "3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies," <i>Journal of Medicinal Chemistry</i> , 48(5):1620-1629, 2005.
	C42	Peng <i>et al.</i> , "3D-QSAR comparative molecular field analysis on opioid receptor agonists SNC80 and its analogs," <i>Journal of Molecular Graphics & Modeling</i> , submitted January 31, 2005.

25521035.1

EXAMINER:



DATE CONSIDERED:

9/20/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)